The 10 most recent market catalysts affecting $HRMY, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Aug 26, 2026
Corporate Catalyst
Neutral
Impact 65
Wolfe Research Initiates Coverage On Harmony Biosciences Hldgs with Outperform Rating, Announces Price Target of $60
Wolfe Research's initiation of coverage on Harmony Biosciences Holdings (HRMY) with an 'Outperform' rating and a $60 price target is a positive development for the company. Analyst…
Aug 5, 2026
Corporate Catalyst
Bullish
Impact 85
Harmony Biosciences Says New Data Supports Neurology Pipeline
Harmony Biosciences reported record Q2 2026 revenue of $261.3 million, surpassing analyst estimates, and an EPS of $1.28, significantly beating the consensus. This strong financial…
Aug 4, 2026
Corporate Catalyst
Bullish
Impact 55
Needham Maintains Buy on Harmony Biosciences Hldgs, Raises Price Target to $50
Needham analyst Ami Fadia maintained a 'Buy' rating on Harmony Biosciences Hldgs (HRMY) and raised the price target from $45 to $50. This action signals increased analyst confidenc…
Aug 4, 2026
Corporate Catalyst
Bullish
Impact 75
Harmony Biosciences shares are trading higher after the company reported better-than-expected Q2 financial results.
This headline signifies a direct positive corporate catalyst for Harmony Biosciences. Better-than-expected financial results typically lead to increased investor confidence and upw…
Aug 4, 2026
Corporate Catalyst
Bullish
Impact 92
Harmony Biosciences Q2 EPS $1.28 Beats $0.94 Estimate, Sales $261.300M Beat $248.406M Estimate
Harmony Biosciences announced Q2 earnings per share of $1.28, significantly exceeding the analyst consensus of $0.94, and sales of $261.300 million, beating the $248.406 million es…
Aug 4, 2026
Corporate Catalyst
Bearish
Impact 55
Harmony Biosciences Hldgs Affirms FY2026 Sales Guidance of $1.000B-$1.040B vs $1.020B Est
Harmony Biosciences has filed an 8-K to affirm its fiscal year 2026 sales guidance. The guidance range of $1.000 billion to $1.040 billion remains unchanged, and it encompasses the…
Jul 31, 2026
Corporate Catalyst
Bullish
Impact 55
Mizuho Maintains Outperform on Harmony Biosciences Hldgs, Raises Price Target to $51
Mizuho analyst Graig Suvannavejh maintained an 'Outperform' rating on Harmony Biosciences Holdings (HRMY) and raised the price target by a dollar, from $50 to $51. This action indi…
Jul 16, 2026
Corporate Catalyst
Neutral
Impact 55
HC Wainwright & Co. Reiterates Buy on Harmony Biosciences Hldgs, Maintains $55 Price Target
HC Wainwright & Co. analyst Patrick R. Trucchio has reaffirmed a 'Buy' rating and a $55 price target for Harmony Biosciences Holdings (HRMY). This action signals that the analyst's…
Jul 16, 2026
Corporate Catalyst
Bullish
Impact 75
Harmony Biosciences Reports Preliminary Q2 WAKIX Sales Of ~$261M, Up 30% YoY; Appoints Stephen Mollichella As Interim CFO
Harmony Biosciences reported preliminary Q2 2026 WAKIX sales of $261 million, marking a 30% year-over-year increase and a new quarterly record. This strong performance led the comp…
Jul 16, 2026
Corporate Catalyst
Bearish
Impact 55
Harmony Biosciences Hldgs Affirms Prelim FY2026 Sales Guidance of $1.000B-$1.040B vs $1.014B Est
Harmony Biosciences Holdings (HRMY) has affirmed its preliminary sales guidance for fiscal year 2026, keeping the range at $1.000 billion to $1.040 billion. This action is signific…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.